1. Adlard, R.D., Barker, S.C., Blair, D., and Cribb, T.H. (1993). Comparison of the second internal transcribed spacer (ribosomal DNA) from populations and species of Fasciolidae (Digenea). Int J Parasitol 23, 422–425.
2. Anonymous. (1988). Parasitic diseases: hepatic distomiasis caused by Fasciola hepatica. Wkly Epidemiol Rec (WHO) 63, 109–111.
3. Apt, W., Aguilera, X., Vega, F., Miranda, C., Zulantay, I., Perez, C., Gabor, M., and Apt, P. (1995). Treatment of human chronic fascioliasis with triclabendazol: drug efficacy and serologic response. Am J Trop Med Hyg 52, 532–535.
4. Arjona, R., Riancho, J.A., Aguado, J.M., Salesa, R., and Gonzalez-Macias, J. (1995). Fascioliasis in developed countries: a review of classic and aberrant forms of the disease. Medicine (Baltimore) 74, 13–23.
5. Ashrafi, K., Massoud, J., Houlakuei, K., Mahmoodi, M., Jo-Afshani, M.A., Valero, M.A., Fuentes, M.V. Khoubbane, M., Bargues, M.D., and Mas-Coma, S. (2004). Evidence suggesting that Fasciola gigantica may be the most prevalent causal agent of fasciolia-sis in the endemic province of Gilan, northern Iran. Iranian J Public Health 33, 31–37.